Apogem Capital LLC Albireo Pharma, Inc. Transaction History

Apogem Capital LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$16.32 - $26.37 $7,621 - $12,314	-467 Reduced 1.33%	34,524 $668,000
Q2 2022 Aug 15, 2022	SELL	$18.54 - $37.29 $9,214 - $18,533	-497 Reduced 1.4%	34,991 $695,000
Q1 2022 May 16, 2022	SELL	$23.94 - $33.74 $74,525 - $105,032	-3,113 Reduced 8.06%	35,488 $1.06 Million
Q4 2021 Feb 14, 2022	BUY	$21.19 - $31.29 $91,117 - $134,547	4,300 Added 12.54%	38,601 $899,000
Q3 2021 Nov 15, 2021	BUY	$27.36 - $35.98 $322,957 - $424,707	11,804 Added 52.47%	34,301 $1.07 Million
Q2 2021 Aug 16, 2021	BUY	$28.9 - $36.87 $271,746 - $346,688	9,403 Added 71.81%	22,497 $791,000
Q1 2021 May 14, 2021	BUY	$32.03 - $42.85 $77,928 - $104,254	2,433 Added 22.82%	13,094 $462,000
Q4 2020 Feb 16, 2021	BUY	$31.56 - $42.16 $336,461 - $449,467	10,661 New	10,661 $400,000

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Apogem Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Apogem Capital LLC with notifications on news.